Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease.
Lake-Bakaar
Gerond
G
Dustin
Lynn
L
McKeating
Jane
J
Newton
Kimberley
K
Freeman
Victoria
V
Frost
Simon D W
SD
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology*; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D003449:Cryoglobulinemia / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D016174:Hepacivirus / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000276:immunology* / Q000821:virology; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D007262:Infusions, Intravenous; D007700:Kinetics; D008297:Male; D012367:RNA, Viral / Q000097:blood; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome; D014766:Viremia / Q000097:blood / Q000276:immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007075:Immunoglobulin M; D012367:RNA, Viral; D000069283:Rituximab; D000410:Alanine Transaminase